BioLineRx Ltd. Reports Second Quarter 2013 Results
8/6/2013 7:06:21 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
JERUSALEM, Aug. 6, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended June 30, 2013.
•BL-1040 (ventricular remodeling) – The PRESERVATION I clinical trial, a CE-Mark registration trial, is proceeding as scheduled – there are currently 36 active sites in 9 countries, including 7 leading sites in the U.S.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by